Association details:
Biomarker:MLH1 mutation
Cancer:Prostate Cancer
Drug:Lynparza (olaparib) (PARP inhibitor)
Evidence Level:
Sensitive: C2 – Inclusion Criteria

Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL)

...- Documented germline/somatic mutation in any of the Homologous Recombination Repair genes, including among others, BRCA1 or BRCA2, ATM, Fanconi genes, CHEK2, mutL homolog 1 (MLH1), mutS homologue 2 (MSH2), mutS homolog 6 (MSH6), PMS2, PALB2, RAD51C, MRE11 that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function)....
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials

Prognostic Role of DNA Damage Response Genes Mutations and their Association With the Sensitivity of Olaparib in Prostate Cancer Patients

Published date:
The findings revealed that the mutation population of ATR, BLM, and MLH1 appears more sensitive to Olaparib….Furthermore, mutations in ATR, BLM, and MLH1 or the expression of POLR2L, PMS1, FANCE, and other genes significantly influence Olaparib sensitivity, which may be underlying therapeutic targets in the future....Intriguingly, we discovered that the expression of POLR2L, PMS1, FANCE, WRN, and other genes was closely related to Olaparib sensitivity, suggesting that these genes may be underlying therapeutic targets in clinical practice.